Please orient your device to the portrait position
to return to the site

XOLAIR Access Solutions

Before you can start taking XOLAIR, your doctor's office will check with your health plan to see if your XOLAIR treatment is covered. This process can take about 2 weeks. XOLAIR Access Solutions can assist your doctor's office with this process.

XOLAIR Access Solutions can help

XOLAIR Access Solutions works closely with your doctor's office to:

  • Check with your health plan to see if your treatment for XOLAIR is covered
  • Guide you and your doctor's office through the process of getting XOLAIR
  • Find out if there are other XOLAIR Patient Assistance Programs available to you

Once the process starts, you'll be asked to fill out some forms and return any phone calls. Be sure to respond quickly. This keeps the process moving. You can contact XOLAIR Access Solutions with any questions at 1-800-704-6610.

Access Solutions

How do I get started with XOLAIR Access Solutions?

What is this? WHAT IS MY Q’S? Click on highlighted questions throughout the site to add that question to My Q’s. When you’re done you can print your list of questions to bring to the doctor. Close
Print

You last added:

    0

    What is XOLAIR?

    XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat adults and children 12 years of age and older with moderate to severe persistent asthma whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if you have allergies to year-round allergens.

    XOLAIR is not used to treat other allergic conditions, acute bronchospasm or status asthmaticus.

    IMPORTANT SAFETY INFORMATION

    What is the most important information I should know about XOLAIR?

    A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

    • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
    • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom"
    • flushing, itching, hives, or feeling warm
    • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

    Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider's office or treatment center.

    Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.

    Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:

    • have any other allergies (such as food allergy or seasonal allergies)
    • have sudden breathing problems (bronchospasm)
    • have ever had a severe allergic reaction called anaphylaxis
    • have or have had a parasitic infection
    • have or have had cancer
    • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
    • if you become pregnant while taking XOLAIR, talk to your healthcare provider about registering with the XOLAIR Pregnancy Registry. You can get more information and register by calling 1-866-4XOLAIR (1-866-496-5247) or visit www.XOLAIRpregnancyregistry.com.
    • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.

    How should I receive Xolair?

    • Xolair should be given by your healthcare provider, in a healthcare setting.
    • Xolair is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.
    • In asthma patients, a blood test for a substance called IgE must be performed prior to starting Xolair to determine the appropriate dose and dosing frequency. Do not decrease or stop taking any of your other asthma medicine unless your healthcare providers tell you to.
    • You may not see improvement in your symptoms right away after Xolair treatment.

    What are the possible side effects of XOLAIR? XOLAIR may cause serious side effects, including:

    • See, "What is the most important information I should know about XOLAIR" regarding the risk of anaphylaxis.
    • Cancer. People who receive treatment with XOLAIR may have a higher chance for getting certain types of cancer.
    • Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
    • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
    • Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether this is caused by Xolair.

    The most common side effects of XOLAIR:

    • Pain especially in your arms and legs, dizziness, feeling tired, skin rash, bone fractures, and pain or discomfort of your ears.

    These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.

    You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at 888-669-6682.

    Please see full Prescribing Information, including Medication Guide, for additional important safety information.

    ©2016 Genentech USA, Inc. and Novartis Pharmaceuticals Corporation. All rights reserved.

    This Web site is a service of Genentech USA, Inc. and Novartis Pharmaceuticals Corporation and is intended for U.S. residents only.